US Stem Cell Inc (USRM)

[fast.money]

We have good news out on the Medical Conference! Check out the news!!!

Bioheart, Inc. to Present Clinical Trial Results at the Age Management Medicine Group Conference

http://finance.yahoo.com/news/bioheart-inc-present-clinical-trial-120000747.html

SUNRISE, FL--(Marketwired - Apr 22, 2014) - Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the 16th Clinical Applications for Age Management Medicine Group conference and Scientific Seminar in Orlando, Florida April 24-27. It is the goal of the Age Management Medicine Group (AMMG) to provide education and information on the specialty of Age Management Medicine to physicians and healthcare professionals through evidence-based continuing medical education conferences, workshops, seminars, publications and web media.

Kristin Comella, Bioheart's Chief Scientific Officer, will present for the first time the Angel 6 month trial data. At the 6 month time point, patients are demonstrating an average improvement in exercise capacity or a six minute walk test of approximately 68 meters as compared to an average improvement of 47 meters at 3 months. Eighty percent of the patients showed an improvement in their exercise capacity from 3 months to 6 months post stem cell injection.

Another end point in the study is ejection fraction (EF) by echocardiogram. At the 3 month time point, 100% of the patients demonstrated either improvement or stayed the same. After 3 months, patients showed an average absolute improvement of 3 percentage points in ejection fraction. The patients continued to improve from 3 months to 6 months with a statistically significant average absolute improvement of 10 percentage points (p=0.01).